Clinical Effect of Tangshen Prescription Combined with Beraprost Sodium on Inflammatory Factors and Safety of Treatment of Diabetic Kidney Disease

ZHANG Chuan-fu; LU Jian-rao; WANG Xin-hua; CHEN Xiu-feng; CHEN Xian

doi:10.13422/j.cnki.syfjx.2017210173

您当前的位置：

首页 >

文章列表页 >

Clinical Effect of Tangshen Prescription Combined with Beraprost Sodium on Inflammatory Factors and Safety of Treatment of Diabetic Kidney Disease

更新时间：2024-01-04

- Clinical Effect of Tangshen Prescription Combined with Beraprost Sodium on Inflammatory Factors and Safety of Treatment of Diabetic Kidney Disease
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 21, Pages: 173-178(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017210173
  CLC： R587.2;R692.9
- Published：2017
- 稿件说明：
移动端阅览
ZHANG Chuan-fu, LU Jian-rao, WANG Xin-hua, et al. Clinical Effect of Tangshen Prescription Combined with Beraprost Sodium on Inflammatory Factors and Safety of Treatment of Diabetic Kidney Disease[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(21): 173-178.
DOI：

ZHANG Chuan-fu, LU Jian-rao, WANG Xin-hua, et al. Clinical Effect of Tangshen Prescription Combined with Beraprost Sodium on Inflammatory Factors and Safety of Treatment of Diabetic Kidney Disease[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(21): 173-178. DOI： 10.13422/j.cnki.syfjx.2017210173.

摘要

目的：观察糖肾方联合贝前列素钠对糖尿病肾病患者（DKD）炎症因子的影响及安全性。方法：单纯应用糖肾方（中药组）、贝前列素钠（西药组）与两者联合应用（合用组）进行随机平行对照研究，观察各组患者给药前后临床疗效、中医证候积分、空腹血糖（FBG）、尿蛋白排泄率（UAER）及相关炎性细胞因子转化生长因子（TGF）-β1，肿瘤坏死因子（TNF）-α及白细胞介素（IL）-18等的变化。结果：与治疗前比较，各组治疗后各项指标均降低；与西药组比较，中药组患者FBG水平明显降低（P < 0.05）；与中药组比较，西药组患者IL-18水平明显降低（P < 0.05）；与中药组、西药组比较，合用组患者临床总有效率升高（P < 0.05），合用组患者的肾气虚相关症状（腰膝酸软、口干不欲饮）积分，FBG水平，UAER水平以及炎症因子水平均明显降低（P < 0.05）；与西药组比较，合用组患者脾气虚相关症状（纳差乏力、肢体浮肿）积分明显降低（P < 0.05）。3组患者研究过程中均未发现严重不良反应。结论：糖肾方与贝前列素钠联用，可提高降低患者尿蛋白，改善炎症状态的作用，对临床期DKD有较好的治疗效果。

Abstract

Objective: To observe the effect of Tangshen prescription combined with beraprost sodium on inflammatory factors and safety of patients with diabetic kidney disease (DKD). Method: The randomized parallel control study was carried on among three groups

which were the traditional Chinese medicine(TCM) group (Tangshen prescription)

the western medicine group (beraprost sodium) and the combined group (combination of the two medicines). Clinical curative effect

symptom score

fasting blood glucose (FBG)

urinary albumin excretion rate (UAER)

and relevant inflammatory factors

such as interleukin (IL)-18

tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β1 were observed before and after the administration. Result: After treatment

all of the indexes in each group were significantly reduced

compared with before treatment. Compared with western medicine group

the level of FBG in TCM group was significantly lower

with statistically significant differences (P < 0.05). The level of IL-18 in western medicine group was lower than that of traditional Chinese medicine group

with statistically significant differences (P < 0.05). Compared with group

the total clinical efficiency of combined group increased

with statistically significant differences (P < 0.05); and it was also increased in combined group

compared with western medicine group

with statistically significant differences (P < 0.01). In improving the deficiency of spleen Qi (soreness and weakness of waist and knees and thirst without desire to drink)

and reducing the levels of FBG

UAER and inflammatory factors

the combined group was superior to both group and western medicine group

with statistically significant differences (P < 0.05). In releasing the deficiency of spleen Qi (fatigue

anorexia and swollen limbs)

combined group was superior to western medicine group

with statistically significant differences (P < 0.05). No serious adverse reaction was found in three groups. Conclusion: Tangshen prescription combined with beraprost sodium could enhance the effect of reducing proteinuria and inflammation

with a better effect in treatment of DKD at the clinical stage.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy of Tangshen Prescription Combined with Guanchang Enema for Type 2 Ⅳ-stage Diabetic Kidney Disease and Effect on Inflammatory Factors

Effect of Acupuncture Combined with Modified Shengyutang on Clinical Efficacy and T-lymphocyte Subsets in Patients with Cervical Spondylotic Radiculopathy of Qi-blood Deficiency

Effect of Tangshen'an on Nrf2/ARE Pathway in Human Renal Mesangial Cells Under High Glucose

Zhenzhu Tiaozhi Capsules Reduce Renal Lipid Deposition and Inflammation in Mouse Model of Diabetic Kidney Disease via SCAP-SREBP-1c/NLRP3 Signaling Pathway

Effect of Shenkang Injection on Podocyte Apoptosis and GRP78/CHOP Signaling Pathway in db/db Mice with Diabetic Kidney Disease Based on Endoplasmic Reticulum Stress

Related Author

HU Jing

CAO Zi-feng

WANG Qin-jian

WANG Yan

LI Du

YAO Yu-shan

ZHANG Xue-chen

WANG Mei

Related Institution

Henan Province Hospital of Traditional Chinese Medicine

Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine， Guangdong Pharmaceutical University

School of Traditional Chinese Medicine， Beijing University of Chinese Medicine

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

The First Affiliated Hospital of Hunan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰